Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
BOSTON — Inozyme Pharma, Inc. (Nasdaq: INZY) is a leading clinical-stage biopharmaceutical company dedicated to creating innovative therapies for rare diseases that affect bone health and blood vessel function. The company is excited to share that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer, will join a fireside chat at the upcoming 2024 Wells Fargo Healthcare Conference.
Event Details
This engaging fireside chat is set for Thursday, September 5, 2024, from 3:45 to 4:20 PM ET. Those interested in hearing insights from Dr. Winton can tune in to a live webcast of the session, available in the Investor Relations section of Inozyme's official website. A recording will also be accessible for a limited time after the live event concludes.
About Inozyme Pharma
Inozyme Pharma is committed to advancing biopharmaceuticals, particularly for rare diseases associated with deficiencies in the PPi-Adenosine Pathway. Their research emphasizes the crucial role of the ENPP1 enzyme, responsible for producing inorganic pyrophosphate (PPi). When this enzyme is disrupted, it can lead to severe conditions that impact musculoskeletal, cardiovascular, and neurological health.
Key Therapeutic Focus
One of the most critical conditions that Inozyme addresses is ENPP1 Deficiency, a disease that results in significant morbidity and mortality. The company's leading candidate, INZ-701, is an enzyme replacement therapy designed to boost levels of PPi and adenosine in patients affected by these deficiencies. This therapy marks a significant step forward in the potential treatment of conditions such as calciphylaxis and ABCC6 Deficiency.
Clinical Development and Impact
As Inozyme Pharma progresses with the clinical development of INZ-701, the company is dedicated to correcting the pathological conditions arising from these deficiencies. By focusing on the mineralization processes and regulating smooth muscle cells in blood vessels, INZ-701 aims to alleviate the effects of diseases caused by disrupted enzymes and biological pathways in affected patients.
Long-term Vision
Inozyme’s long-term vision is not only about addressing immediate medical challenges but also about improving the quality of life for patients through groundbreaking therapies. Their focused efforts to understand and manipulate the PPi-Adenosine Pathway could lead to significant breakthroughs that redefine care standards in the biopharmaceutical industry.
Company Information and Contacts
Inozyme Pharma is continually expanding its presence in the biopharmaceutical sector, attracting interest from investors and stakeholders. With a strong commitment to research excellence and patient-focused therapeutic development, Inozyme is well-positioned for future growth and innovation.
For comprehensive information regarding Inozyme Pharma’s therapy candidates, ongoing clinical trials, or future events, their official website serves as a valuable resource.
Frequently Asked Questions
What is Inozyme Pharma known for?
Inozyme Pharma specializes in developing innovative treatments for rare diseases that impact bone health and blood vessel function.
When is the upcoming event featuring Dr. Matt Winton?
The fireside chat will be held on September 5, 2024, from 3:45 to 4:20 PM ET.
What is the primary goal of Inozyme's lead candidate, INZ-701?
INZ-701 aims to increase the levels of inorganic pyrophosphate and adenosine to treat diseases associated with deficiencies in these crucial molecules.
How does Inozyme Pharma plan to improve patient outcomes?
By targeting the PPi-Adenosine Pathway, Inozyme Pharma seeks to rectify adverse conditions related to mineralization and chronic diseases.
Where can more information about Inozyme be found?
Interested individuals can visit Inozyme’s official website for detailed insights into their research and developments.
